29. Level of M2BPGi in chronic hepatitis B patients and in liver cirrhosis patients
Main Article Content
Abstract
Chronic hepatitis B is the leading cause of cirrhosis in Vietnam, making early detection of fibrosis stages crucial for disease management. The study aimed to investigate M2BPGi levels and related factors in two patient groups: those with chronic hepatitis B and those with cirrhosis due to hepatitis B. A cross-sectional study conducted on 90 patients with hepatitis B and 52 patients with cirrhosis due to hepatitis B was carried out at Hanoi Medical University Hospital and the Institute of Gastroenterology and Hepatology from August 2023 to June 2024. The study results recorded a median M2BPGi level of 2.56 COI in the cirrhosis group and 0.68 COI in the chronic hepatitis B group. There was a statistically significant increase in M2BPGi levels across fibrosis stages on ARFI (F0-F4), and fibrosis indices APRI, FIB-4, with a p-value of less than 0.05. Spearman correlation analysis showed that M2BPGi levels had a moderate to strong correlation with paraclinical indices such as AST, ALT, PT, Albumin, PLT, AFP, fibrosis indices APRI, FIB-4, and ARFI velocity. These findings suggest that the M2BPGi biomarker holds great potential for early detection of fibrosis in patients with chronic hepatitis B.
Article Details
Keywords
Chronic Hepatitis B, Cirrhosis, M2BPGi
References
2. Rajbhandari R, Chung RT. Treatment of Hepatitis B: A Concise Review. Clinical and translational gastroenterology. Sep 15 2016; 7(9): e190. doi:10.1038/ctg.2016.46.
3. Bui HH, Nguyen ST, Phan ST, Nguyen KM, Nguyen CD. Evaluating M2BPGi as a Marker for Liver Fibrosis in Patients with Chronic Hepatitis B. Digestive diseases and sciences. Dec 2023; 68(12): 4407-4417. doi:10.1007/s10620-023-08143-5.
4. Yoshiji H, Nagoshi S, Akahane T, et al. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. Journal of gastroenterology. Jul 2021; 56(7): 593-619. doi:10.1007/s00535-021-01788-x.
5. Pham TTT, Ho DT, Nguyen T. Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population. World journal of hepatology. May 27 2020; 12(5): 220-229. doi:10.4254/wjh.v12.i5.220.
6. Bộ Y tế. Chẩn đoán và điều trị bệnh Viêm Gan vi rút B. Quyết định số: 3310/QĐ-BYT. (2019).
7. Kim BK, Kim DY, Park JY, et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int. Apr 2010; 30(4): 546-53. doi:10.1111/j.1478-3231.2009.02192.x.
8. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of hepatology. Aug 2017; 67(2): 370-398. doi:10.1016/j.jhep.2017.03.021.
9. Vincent JP, Ndow G, Ogawa S, et al. Mac-2 binding protein glycosylation isomer (M2BPGi) to evaluate liver fibrosis and cancer in HBV-infected patients in West Africa. Journal of global health. Nov 12 2022; 12:04076. doi:10.7189/jogh.12.04076.
10. Mak LY, Wong DK, Cheung KS, Seto WK, Lai CL, Yuen MF. Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. Clinical and translational gastroenterology. Jun 19 2018; 9(6): 163. doi:10.1038/s41424-018-0020-9.